Skip to content
Screener

Glaukos GKOS Accrued Expenses

Accrued Expenses at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$3.48B
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.97B
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
$4.67M-10.8%
Schering-Plough logo
Schering-PloughSGP
$2.18M+70.2%
Bausch + Lomb logo
Bausch + LombBLCO
$1.42B+4.3%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$36.49M+17.4%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.08B+98.7%
Enterprise value$10.07B+98.3%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemJune 30, 2026December 31, 2025
Liabilities and stockholders' equity
Current liabilities:
Accounts payable$19,139$24,624
Accrued liabilities83,19076,651
Total current liabilities102,329101,275
Operating lease liability35,49135,767
Finance lease liability67,34568,109
Deferred tax liability, net441441

Item 1. Financial Statements

FAQ

What is Glaukos's accrued expenses?
Glaukos (GKOS) reported accrued expenses of $83.19M in Q2 2026.
How has Glaukos's accrued expenses changed year-over-year?
Glaukos's accrued expenses increased by 27.1% year-over-year, from $65.45M to $83.19M.
What is the long-term trend for Glaukos's accrued expenses?
Over 5 years (2020 to 2025), Glaukos's accrued expenses has grown at a 11.1% compound annual growth rate (CAGR), from $45.33M to $76.65M.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.

Ask your AI about Glaukos's accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude